1. Introduction {#sec1}
===============

There is an increasing need for new therapies to treat cancer, especially in the advanced stages. There is much interest in naturally derived compounds as targets for potential cancer treatment. Many plant derived principles have shown excellent anti-cancer activity in the past. The anticancer drugs such as Etoposide, Vincristine, and Taxanes to name a few were derived from plants. *Withania somnifera* (Ashwagandha) or the Indian Ginseng has been used in Ayurveda for centuries for the treatment of several disorders. It possesses numerous pharmacological properties including neuroprotection, anti-inflammation, aphrodisiac, rheumatism, insomnia, and goiter among others [@bib1]. An extract from the roots contains a group of biologically active constituents known as withanolides. The chemical structures of withanolides have been studied and they are widely distributed in the family Solanaceae.

Withaferin- A (WA) is a therapeutically active withanolide reported to be present in roots and leaves of the plant. In several preclinical studies, it has shown significant anticancer activity. The structure of WA is shown in [Fig. 1](#fig1){ref-type="fig"}. WA has been shown to prevent and cure urethane-induced lung tumors in mice, and also inhibit the growth of transplanted sarcoma in mice. Ashwagandha roots possess health-promoting activities, some of the activities of the root extract and its components include inhibition of NF-kappaB and AP-1 transcription factors [@bib2], induction of apoptosis via mitochondria mediated cytochrome c release and caspase activation [@bib3], elicitation of humoral and cell-mediated immune responses by upregulation of Th1-dominant polarization [@bib4] and anti-tumor effects by downregulation of p34cdc2 expression [@bib5]. The leaf extract of Ashwagandha demonstrated an antitumor activity which was mainly associated with its component withanone that selectively activated the p53 pathway in tumor cells [@bib6], [@bib7].Fig. 1Structure of Withaferin A.Fig. 1

WA was tried in mouse sarcoma 180 (S-180) solid and ascites tumor cells that were treated *in vivo* and *in vitro*. On observing via an electron microscope the compound was found to affect these spindle microtubules of cells in metaphase [@bib8]. WA demonstrated a sensitizer enhancement ratio of 1.5 for *in vitro* cell killing of V79 Chinese hamster cells at a non-toxic concentration of approximately 2 μM [@bib9]. WA can inhibit T-cell and B-cell upregulation and proliferation without causing cell death. Thus demonstrating potential as an anti-inflammatory agent [@bib10]. WA shows cytotoxicity in a variety of tumor cell lines. In a study, they have shown that it primarily induces oxidative stress in human leukemia HL-60 cells and in several other cancer cell lines [@bib11]. Genetic studies suggest that it may present an attractive treatment option for triple negative breast cancer (TNBC) which has a poor prognosis [@bib12]. In preclinical data, WA has shown antiproliferative potential and led to apoptosis in MG-63 and U2OS human osteosarcoma cell lines by inducing a ROS-mediated reduction in mitochondrial membrane potential and inhibiting G2/M checkpoint proteins thus fostering cell cycle arrest [@bib13], [@bib14]. Advanced osteosarcoma has limited treatment options. Metastatic disease presents a treatment challenge and patients often have a poor prognosis. Thereby indicating the need for new therapies and options for the advanced stage of the disease. Some of the challenges that have to be surpassed at the clinical level prior to using WA as an anticancer agent are its potency, efficacy and side effects i.e. establishing a safe and effective dosing protocol [@bib15].

Despite being a strong candidate there are no clinical trials in cancer on this product. To determine the established benefits in a clinical setting, we carried out a phase I study in osteosarcoma patients. We selected a standardized root extract of *W. somnifera* containing 4.5% of WA w/w for the Phase I trial. *W. somnifera* is taken with clarified butter in Ayurveda, the traditional Indian medicine. We used a formula in which the extract was processed as per Ayurveda text in clarified butter. Our objectives for this study were to determine the presence of any dose limiting toxicity (DLT) at day 30 and to evaluate the safety and pharmacokinetics of WA containing formulation in patients with advanced stage high-grade osteosarcoma.

2. Materials and methods {#sec2}
========================

The study was approved by our Institutional Ethics Committee which is presently registered with the Drugs Controller General of India (IEC registration number: ECR/170/Inst/MH/2013). The trial was registered in clinicaltrials.gov ([ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0030} Identifier: [NCT00689195](NCT00689195){#intref0035}).

2.1. Patients and setting {#sec2.1}
-------------------------

It was a single-center phase I dose escalation study conducted at a tertiary care cancer hospital in western India. We recruited 13 patients who were willing to participate and who met the eligibility criteria, the enrolled patients provided their written informed consent to participate in the study.

The eligibility criteria for the study included: 1) Children and adults aged between 8 and 65 years 2) Histologically proven high grade osteosarcoma of the extremity and 3) Relapsed disease after primary line of treatment who are unsuitable or refuse secondary chemotherapy. Exclusion criteria included: 1) Pregnant/lactating women, 2) Those requiring concomitant treatment with CYP inducers or inhibitors and 3) Those without good venous access.

2.2. Study intervention {#sec2.2}
-----------------------

A standardized root extract of *W. somnifera* containing 4.5% of WA w/w was used for this study (AshwaMAX 400, Pharmanza Herbal Pvt Ltd., Gujarat, India). Each 400 mg capsule of AshwaMAX contained 18 mg of WA. The extract was processed in clarified butter as prescribed in the traditional texts of Ayurveda.

2.3. Study design {#sec2.3}
-----------------

Our study design was a classic 3 + 3 dose escalation approach as shown in [Fig. 2](#fig2){ref-type="fig"}. The purpose of phase 1 trials is to determine the maximum tolerated dose (MTD). 3 + 3 designs are easy to operate and identify MTD with acceptable level of precision. A major limitation of 3 + 3 design is that it enrolls a significant proportion of patients at sub-therapeutic doses [@bib16]. However, its conservative dose escalation strategy minimizes the risk of exposure to toxic doses of the investigational product. We had earlier conducted a 28-day repeated dose toxicity study in rats, where we used a standardized *W. somnifera* extract containing 4.5% of WA. The No observed adverse effect level (NOAEL) found in the study was 2000 mg/kg. The corresponding Human Equivalent Dose (HED) is approximately 325 mg/kg/day. A safety factor of five was applied to obtain the Maximum Recommended Starting Dose (MRSD) of 65 mg/kg/day of the formula in humans [@bib17]. Considering the average human weight to be 60 kg we arrived at an MRSD of 3900 mg/day. In the present study the starting dose of *W.* *somnifera* extract used is 1600 mg, which was gradually escalated to 4800 mg/day. The highest dose of WA at which ≤1 out of 6 patients had dose limiting toxicities (DLTs) was defined as the Maximum Tolerated Dose (MTD). Dose limiting toxicity was defined as any grade 3 non-hematological or grade 4 hematological event related to Withaferin-A, based on the National Cancer Institute\'s Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The dose escalation cohorts comprised of 2 capsules BID, 3 capsules BID, 4 capsules BID and 4 capsules TID corresponding to daily doses of 72, 108, 144 and 216 mg of WA. Three patients were enrolled in each cohort and the last patient was observed for at least 30 days for any dose limiting toxicity before progressing to a higher cohort.Fig. 23 + 3 Dose escalation study design for phase I clinical trials. DLT = Dose Limiting Toxicity; MTD = Maximum Tolerated Dose. All DLTs were evaluated at day 30.Fig. 2

2.4. Safety and pharmacokinetics sampling and analysis {#sec2.4}
------------------------------------------------------

Pharmacokinetic samples were collected on day 1 at the following time points -- 0.0 (predose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, 10, 12.0 and 24.0 h after administration and plasma levels were measured using the validated High Performance Liquid Chromatography (HPLC) technique as described by Patial et al. having a limit of quantitation of 50 ng/mL [@bib18]. The chromatographic system used a reverse-phase C18 column with UV--visible detection at 225 nm. The mobile phase consisted of water and acetonitrile applied in a gradient flow. Withaferin-A was extracted by simple protein-precipitation technique. The calibration curve was linear in the concentration range of 0.05--1.6 μg/mL. The method has the desired sensitivity to detect the plasma concentration range of Withaferin-A that is likely to show biological activity based on in vitro data. Patients were followed-up at 3 monthly intervals. Safety evaluation, including clinical examination, detailed history of adverse events, liver function tests, renal function tests and complete blood counts were performed at each visit. WA was administered daily till progression. CTCAE version 3.0 was used for grading adverse events.

3. Results {#sec3}
==========

Thirteen patients meeting the eligibility criteria were enrolled in the dose-escalation trial. Baseline characteristics of the study participants are summarized ([Table 1](#tbl1){ref-type="table"}).Table 1Baseline characteristics of the study population. ALP -- Alkaline Phosphatase.Table 1Patient CharacteristicsNumber Of Patients13Male/Female10/3Median Age (yrs)16 (13--43)Mean Hemoglobin (±SD)[a](#tbl1fna){ref-type="table-fn"} (g/dL)10.62 (±2.53)Mean Sr. Creatinine (±SD)[a](#tbl1fna){ref-type="table-fn"} (mg/dL)0.9 (±0.14)Mean Sr. ALP[a](#tbl1fna){ref-type="table-fn"} (IU/L)597.5 (±849.5)[^1]

A flow chart depicting patient enrollment and allocation procedure that was followed in this study as well as the number of patients starting therapy at each dose is shown in [Fig. 3](#fig3){ref-type="fig"}.Fig. 3Flow chart displaying patient enrollment, allocation, follow-up and evaluation. WA = Withaferin-A, PK = Pharmacokinetics.Fig. 3

3.1. Safety laboratory results {#sec3.1}
------------------------------

One subject in cohort 1 developed worsening of anemia with hemoglobin levels decreasing to 6.9 g/dL at the 3 month follow-up period compared to 7.7 g/dL at baseline. Five subjects (38.46%) had elevations in liver enzymes -- aspartate aminotransferase (AST) and alanine aminotransferase (ALT). All liver enzyme level elevations were grade 1 in severity. AST alone was elevated in one patient, ALT alone in one patient, while 3 patients had combined elevation of ALT and AST ([Table 2](#tbl2){ref-type="table"}).Table 2Frequency of adverse events across cohorts is shown.Table 2Adverse Event72 mg (n = 3)108 mg (n = 3)144 mg (n = 4)216 mg (n = 3)Overall (n = 13)Number of adverse eventsAbnormal LFTs12--25Fatigue1------1Fever--1----1Rash--11--2Diarrhea----1--1Edema------11DLT----------[^2]

3.2. Adverse events {#sec3.2}
-------------------

Eleven adverse events occurred in 8 subjects during the course of the study. Two events occurred in cohort 1 and cohort 3 each, while four events were observed in cohort 2 and three in cohort 4. The adverse events fall into 6 major categories: Fatigue (1), Fever (1), Rash (2), Diarrhea (1), Edema (1) and abnormal LFTs (5). The events were either grade 1 or grade 2 in nature. The adverse events that occurred during the study across the 4 cohorts are shown above in ([Table 2](#tbl2){ref-type="table"}).

3.3. Pharmacokinetic data {#sec3.3}
-------------------------

All patients (N = 13) enrolled in the study contributed samples for pharmacokinetic analysis of WA. There were no detectable levels of Withaferin-A in any of the samples collected.

4. Discussion {#sec4}
=============

*W. somnifera* (WS) has been studied for treatment of several conditions. In one study, subjects with cognitive decline were randomized to either WS 300 mg orally twice daily or placebo for 8 weeks. The study found that WS was effective at improving the immediate and general memory in patients having mild cognitive impairment while also enhancing the executive function, attention, and information processing speed [@bib19]. Another study showed that treatment with the Ashwagandha root extract in adults with chronic stress helped in body weight management and resulted in a significant decrease in body weight, serum cortisol levels and body mass index (BMI) [@bib20]. WA a component of Ashwagandha has been studied for its anticancer activity in many in vitro as well as in vivo preclinical models. However, to date, there have been no clinical studies of WA in cancer have been performed.

Advanced osteosarcoma has limited treatment options and phytochemicals have demonstrated useful anticancer activity in the past. The phytochemical WA is a promising anticancer agent. At the molecular level, it has shown to target multiple cell survival kinase pathways, including NF-kB, PI3 kinase, Protein kinase, Mitogen activated protein kinase among others. WA has been reported to induce apoptosis via intrinsic and extrinsic pathways in human prostate, breast and leukemic cancer cells among others. It has also demonstrated its potential to contribute to its anti-tumor effect both in vitro as well as in vivo [@bib21].

Preclinical studies using orthotropic murine models have demonstrated that oral administration of Withaferin-A is effective against Glioblastoma Multiform (GBM), an aggressive malignancy [@bib22]. It has also shown the ability to induce apoptosis in osteosarcoma U2OS cell lines by generating ROS, also causing cell cycle arrest in osteosarcoma cell lines by inhibition of G2/M checkpoint proteins [@bib13], [@bib14].

In this trial, our aim was to evaluate the safety and pharmacokinetics of WA in an advanced stage, high grade osteosarcoma. The results demonstrated that the formulation was well tolerated by patients up to a dose of 4800 mg, equivalent to 216 mg of WA per day, without any dose limiting toxicity. This was the highest dose that could be administered with reasonable tolerability and patient compliance since patients in the highest dose cohort (216 mg) were receiving a regimen of 4 capsules of WA TID. No DLTs were observed even at the highest dose indicating that higher doses may be tried in patients, but the total dose is limited by the number of capsules a patient can reasonably consume in a day. A standardized extract with higher WA content may circumvent this problem leading to higher doses administered per day at acceptable number of capsules and frequency of administration.

Common side effects observed include elevation of liver enzymes (grade 1) in 5 out of 11 patients and skin rash in 2 out of 11 patients. Other side effects seen include fever, fatigue, edema, and diarrhea (one event each). No grade 3 or grade 4 adverse events were observed.

WA was not detectable in any of the study samples. The method used was an HPLC assay with a sensitivity of 50 ng/mL. At the time of the study only an HPLC system capable of detecting 50 ng/ml was available. Bioavailability of withanolides depends on the extent of their absorption and transportation through the intestinal epithelium. A study conducted to assess the bioavailability of withanolides using an in vitro absorption model i.e the Mandin Darby Canine Kidney system discovered that WA was impermeable or metabolized on passing through the cell layer [@bib23]. However, another study that attempted to analyze the PK of WA and withanolide A (WEA) in mouse plasma after oral administration found that oral absorption of the withanolides was rapid. It also demonstrated that the relative bioavailability of WA was one and a half times more than WEA. The study used the HPLC-ESI-MS/MS assay, which was found to have a sensitivity of 0.484 ng/ml [@bib24], thus suggesting more sensitive analytical techniques are required to characterize the PK of WA in humans. We could not establish bioavailability of WA due to the above reasons.

The IC~50~ of WA lies in the submicromolar level, which translates to a concentration of approximately 470 ng/mL. However, WA is unlikely to be used as a stand-alone agent. The best way to use WA would be in combination with standard chemotherapy. The synergistic effects of Withaferin A were demonstrated in a study where WA, when combined with cisplatin, acted synergistically and was found to enhance antitumor effects on ovarian cell lines by inhibiting cell proliferation, generation of ROS and causing DNA damage leading to apoptosis [@bib25]. Another study shows the potential of WA as a radiosensitizer, the study was performed on mouse melanoma tumor which was, pretreated with WA and followed by local gamma radiation. WA produced a dose dependent increase in growth delay and volume doubling time [@bib26]. The transcription factor NFκB, which regulates inflammation, cell survival and P-glycoprotein expression, plays a major role in inducing resistance to anticancer drugs [@bib27]. It is observed that WA inhibiits NFκB in doxorubicin-resistant K562/Adr cells, and can relieve attenuated caspase activation and induce apoptosis [@bib27]. This makes WA is an attractive compound for chemosensitization and to elicit cell death in chemoresistant cell types. Thus WA can synergize with other anticancer agents and its P-glycoprotein modulating activity can be exploited for improving the oral bioavailability and intratumoral concentrations of co-administered anticancer drugs [@bib27]. Further clinical studies of WA as an adjunctive to chemotherapy in osteosarcoma are warranted. There is also preliminary evidence related to the activity of WA in gastric, thyroid and ovarian cancer. Here again, the utility of WA as an adjunctive treatment to standard modalities could be evaluated.

Other benefits of WA including immunomodulatory effects suggest that it is likely to mitigate/protect for toxicity and side effects of chemotherapy. Being economical as well as a natural phytochemical, development of an improved formulation of Withaferin-A could turn out to be an attractive anticancer treatment option in both the developed and developing countries.

4.1. Limitation {#sec4.1}
---------------

One of the limitations of this study is that the maximum tolerated dose (MTD) was not achieved. The maximum dose used in this study was 216 mg which was likely an underestimation of the possible MTD. Higher doses can be given WA has an improved formulation of higher strength that allows a simpler dosing regimen and frequency of administration is reduced.

The bioanalytical method used in this study had a sensitivity of 50 ng/mL. Sensitivity and specificity of the analytical technique were a limitation of our study. Bioanalytical techniques with higher sensitivity are recommended in subsequent studies.

5. Conclusion {#sec5}
=============

Our phase I study found that oral Withaferin-A in patients with advanced stage, high grade osteosarcoma has a good safety profile. Further phase II studies of WA can be conducted at a dose of 216 mg/day.
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[^1]: Hemoglobin values in g/dL, Serum creatinine values in mg/dL and ALP values in IU/L are those measured at baseline.

[^2]: AE- Adverse Event, DLT- Dose Limiting Toxicity, LFT- Liver Function Tests.
